Supplemental material
Journal of Medical Economics
Volume 26, 2023 - Issue 1
Open access
2,345
Views
2
CrossRef citations to date
0
Altmetric
Oncology
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1
Vicente Escudero-Vilaplanaa Hospital Gregorio Marañón, Madrid, Spain
https://orcid.org/0000-0003-4417-8321
Roberto Collado-Borrella Hospital Gregorio Marañón, Madrid, Spain
https://orcid.org/0000-0001-7639-0082
Javier De Castrob Hospital Universitario La Paz, Madrid, Spain
, Amelia Insac Hospital Clínico Universitario de Valencia, Valencia, Spain
https://orcid.org/0000-0002-3438-6170
Alex Martínezd Hospital Universitari Vall d’Hebron, Barcelona, Spain
, Elena Fernándeze OSI Bilbao-Basurto, Bilbao, Spain
https://orcid.org/0000-0003-1624-8206
Ivana Sullivanf Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
https://orcid.org/0000-0002-0434-3436
Andrés Floresg Roche Farma S.A, Madrid, Spain
, Natalia Arrabalg Roche Farma S.A, Madrid, Spain
, David Carcedoh Hygeia Consulting, Madrid, SpainCorrespondence[email protected]
https://orcid.org/0000-0002-2809-7399
Alba Manzanequei Hospital Universitari Mútua Terrassa, Terrassa, Spain
https://orcid.org/0000-0002-7935-8317
Pages 445-453
|
Received 26 Jan 2023, Accepted 03 Mar 2023, Published online: 30 Mar 2023
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.